Kyntra Bio price to sales ratio KYNB

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 0.2×; May 2025
10-year median: 10.6×
10-year range: 0.2× to 43.0×
Peer median: 0.9×

Kyntra Bio's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2025, at 0.2×.

On the days it had one over the last ten years, its median was 10.6×, from 0.2× in Apr 2025 to 43.0× in Jul 2018.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	0.2×	0.2×	0.4×
2024	0.3×	0.2×	1.7×
2023	0.6×	0.2×	18.8×
2022	12.2×	3.1×	12.6×
2021	4.6×	3.9×	42.5×
2020	28.3×	8.5×	40.7×
2019	11.0×	9.0×	33.7×
2018	25.8×	21.9×	43.0×
2017	33.8×	8.6×	34.1×
2016	7.9×	5.0×	8.6×

Against its peers

Companies in Drug Manufacturers - General nearest Kyntra Bio's size, closest first, today.

Company	Price to sales ratio
KYNBKyntra Bio	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Kyntra Bio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.